Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A clinician-level guide to using alirocumab (Praluent) after bariatric surgery, covering pharmacokinetics, dosing, ODYSSEY OUTCOMES evidence, and practical management for post-bariatric ASCVD patients.
Read clinical reviewA physician-reviewed deep dive into alirocumab's cognitive safety data, covering ODYSSEY OUTCOMES, FDA surveillance, mechanistic studies, and clinical protocols for monitoring cognition in patients on Praluent.
Read clinical reviewA clinician-level review of alirocumab's impact on sexual function, covering ODYSSEY trial data, PCSK9 biology, testosterone pathways, and what patients on Praluent can realistically expect.
Read clinical reviewA clinician-level review of alirocumab's effects on kidney function, covering ODYSSEY OUTCOMES renal sub-analyses, LDL receptor biology in the nephron, eGFR trajectories, and dosing guidance for CKD patients.
Read clinical reviewWhen and how to safely restart alirocumab (Praluent) after an acute illness, including timing, lipid re-testing, drug interactions, and post-ACS considerations supported by ODYSSEY OUTCOMES data.
Read clinical reviewA physician-reviewed, week-by-week guide to your first four weeks on Praluent (alirocumab): when LDL drops, what side effects appear, and what the ODYSSEY OUTCOMES trial data mean for your cardiovascular risk.
Read clinical reviewDoes alirocumab (Praluent) affect appetite or food cravings? A physician-reviewed deep dive into the clinical trial data, proposed mechanisms, and what patients on PCSK9 inhibitor therapy should expect.
Read clinical reviewA clinical review of alirocumab (Praluent) use in patients with autoimmune disease, covering immunogenicity, drug interactions, trial data from ODYSSEY OUTCOMES, and practical prescribing guidance.
Read clinical reviewA comprehensive clinical review of alirocumab (Praluent) and its effects on bone mineral density, fracture risk, and skeletal health, drawing on ODYSSEY trial data, mechanistic research, and current prescribing guidance.
Read clinical reviewA physician-level review of the alirocumab (Praluent) cancer risk signal, covering ODYSSEY OUTCOMES data, FDA labeling, PCSK9 biology, and current clinical guidance for patients on PCSK9 inhibitor therapy.
Read clinical reviewA clinician-level review of alirocumab (Praluent) cardiovascular outcomes data, including ODYSSEY OUTCOMES, long-term LDL targets, safety profile, and practical prescribing guidance.
Read clinical reviewA physician-reviewed comparison of compounded alirocumab versus branded Praluent, covering FDA regulatory status, clinical trial evidence from ODYSSEY OUTCOMES, cost, and who qualifies for each option.
Read clinical reviewA GRADE-level review of alirocumab (Praluent) evidence across ODYSSEY OUTCOMES and related trials, covering MACE reduction, LDL lowering, safety, and guideline recommendations for clinicians managing high-risk ASCVD and familial hypercholesterolemia.
Read clinical reviewA clinician-level review of alirocumab (Praluent) hair loss and skin reactions, drawing on ODYSSEY trial data, FDA labeling, and primary literature to separate real adverse effects from coincidence.
Read clinical reviewA physician-reviewed deep dive into how alirocumab (Praluent) affects liver enzymes, hepatic safety, and what monitoring is required based on ODYSSEY OUTCOMES and FDA labeling.
Read clinical reviewA comprehensive, physician-reviewed look at alirocumab (Praluent) and its effects on mental health, mood, cognition, and neuropsychiatric outcomes, grounded in ODYSSEY OUTCOMES and post-market data.
Read clinical reviewA clinician-level review of how alirocumab (Praluent) affects lipid metabolism, hepatic VLDL secretion, adipose tissue lipolysis, and whether PCSK9 inhibition meaningfully changes energy expenditure. Covers ODYSSEY OUTCOMES data and emerging mechanistic evidence.
Read clinical reviewA physician-level review of alirocumab (Praluent) dosing, microdosing rationale, ODYSSEY OUTCOMES data, and current ACC/AHA guideline recommendations for PCSK9 inhibition in high-risk patients.
Read clinical reviewEvidence-based strategies for preserving muscle health in patients on alirocumab (Praluent), covering statin-intolerance background, ODYSSEY trial data, monitoring protocols, and dose optimization.
Read clinical reviewA clinical guide for physicians and patients on why alirocumab (Praluent) stops working, how to identify true non-response, and evidence-based strategies to restore LDL-C reduction.
Read clinical reviewEvidence-based guidance on when to pause alirocumab (Praluent) before surgery, covering pharmacokinetics, bleeding risk, lipid rebound, and restart timing for cardiovascular patients.
Read clinical reviewStopping alirocumab (Praluent) causes LDL-C to rise back toward baseline within 8 to 12 weeks. Learn the clinical evidence, rebound timeline, cardiovascular risk implications, and how to discontinue safely.
Read clinical reviewA physician-reviewed guide to alirocumab (Praluent) seasonal use considerations, covering cold-chain storage, LDL variability across seasons, injection site management, and adherence strategies backed by primary literature.
Read clinical reviewA clinician-level review of alirocumab (Praluent) and sleep architecture. Covers PCSK9 biology, ODYSSEY OUTCOMES safety data, lipid-lowering drug comparisons, and practical guidance for patients reporting sleep changes.
Read clinical reviewBoard-reviewed protocols for traveling with alirocumab (Praluent), covering cold-chain storage, timezone-shifted dosing, airport security, and post-travel LDL monitoring. Backed by primary literature.
Read clinical review